An economic model: Value of antimicrobial-coated sutures to society, hospitals, and third-party payers in preventing abdominal surgical site infections

Infection Control and Hospital Epidemiology

Volumn 35, Issue 8, 2014, Pages 1013-1020

  Singh, Ashima ^a   Bartsch, Sarah M ^b   Muder, Robert R ^c   Lee, Bruce Y ^b  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; CIPROFLOXACIN; LINEZOLID; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; VANCOMYCIN; TOPICAL ANTIINFECTIVE AGENT; TRICLOSAN;

ABDOMINAL SURGERY; ARTICLE; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HOSPITALIZATION; HUMAN; LIFE EXPECTANCY; MORTALITY; SENSITIVITY ANALYSIS; SIMULATION; SURGICAL INFECTION; SUTURE; TRICLOSAN COATED SUTURE; ABDOMEN; ADOLESCENT; ADULT; AGED; CHILD; COST BENEFIT ANALYSIS; COST CONTROL; DRUG COST; ECONOMIC MODEL; ECONOMICS; HEALTH ECONOMICS; INFANT; MIDDLE AGED; PRESCHOOL CHILD; PROCEDURES; REIMBURSEMENT; RISK FACTOR; SURGERY; SURGICAL WOUND INFECTION; VERY ELDERLY; YOUNG ADULT;

ABDOMEN; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS, LOCAL; CHILD; CHILD, PRESCHOOL; COST SAVINGS; COST-BENEFIT ANALYSIS; DRUG COSTS; ECONOMICS, HOSPITAL; HUMANS; INFANT; INSURANCE, HEALTH, REIMBURSEMENT; MIDDLE AGED; MODELS, ECONOMIC; RISK FACTORS; SURGICAL WOUND INFECTION; SUTURES; TRICLOSAN; YOUNG ADULT;

EID: 84904395866     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/677163     Document Type: Article

References (60)

1. Perencevich EN, Sands KE, Cosgrove SE, Guadagnoli E, Meara E, Platt R. Health and economic impact of surgical site infections diagnosed after hospital discharge. Emerg Infect Dis 2003; 9(2): 196-203.
2. Hawn MT, Vick CC, Richman J, et al. Surgical site infection prevention: time to move beyond the surgical care improvement program. Ann Surg 2011; 254(3): 494-501. doi: 10. 1097/SLA. 0b013e31822c6929.
3. Pastor C, Artinyan A, Varma MG, Kim E, Gibbs L, Garcia-Aguilar J. An increase in compliance with the Surgical Care Improvement Project measures does not prevent surgical site infection in colorectal surgery. Dis Colon Rectum 2010; 53(1): 24-30.
4. McHugh SM, Collins CJ, Corrigan MA, Hill AD, Humphreys H. The role of topical antibiotics used as prophylaxis in surgical site infection prevention. J Antimicrob Chemother 2011; 66(4): 693-701.
5. Watanabe A, Kohnoe S, Shimabukuro R, et al. Risk factors associated with surgical site infection in upper and lower gastrointestinal surgery. Surg Today 2008; 38(5): 404-412.
6. de Oliveira AC, Ciosak SI, Ferraz EM, Grinbaum RS. Surgical site infection in patients submitted to digestive surgery: risk prediction and the NNIS risk index. Am J Infect Control 2006; 34(4): 201-207.
7. Blumetti J, Luu M, Sarosi G, et al. Surgical site infections after colorectal surgery: do risk factors vary depending on the type of infection considered? Surgery 2007; 142(5): 704-711.
8. Rahbari NN, Knebel P, Diener MK, et al. Current practice of abdominal wall closure in elective surgery: is there any consensus? BMC Surg 2009; 9: 8.
9. Alexander JW, Kaplan JZ, Altemeier WA. Role of suture materials in the development of wound infection. Ann Surg 1967; 165(2): 192-199.
10. Kobayashi S, Ito M, Sugito M, Kobayashi A, Nishizawa Y, Saito N. Association between incisional surgical site infection and the type of skin closure after stoma closure. Surg Today 2011; 41(7): 941-945.
11. Baracs J, Huszár O, Sajjadi SG, Horváth ÖP. Surgical site infections after abdominal closure in colorectal surgery using triclosan-coated absorbable suture (PDS Plus) vs. uncoated sutures (PDS II): a randomized multicenter study. Surg Infect (Larchmt) 2011; 12(6): 483-489.
12. Rašić Ž, Schwarz D, Adam VN, et al. Efficacy of antimicrobial triclosan-coated polyglactin 910 (Vicryl* Plus) suture for closure of the abdominal wall after colorectal surgery. Coll Antropol 2011; 35(2): 439-443.
13. Justinger C, Moussavian MR, Schlueter C, Kopp B, Kollmar O, Schilling MK. Antibacterial coating of abdominal closure sutures and wound infection. Surgery 2009; 145(3): 330-334.
14. Justinger C, Schuld J, Sperling J, Kollmar O, Richter S, Schilling MK. Triclosan-coated sutures reduce wound infections after hepatobiliary surgery: a prospective non-randomized clinical pathway driven study. Langenbecks Arch Surg 2011; 396(6): 845-850.
15. Mingmalairak C, Ungbhakorn P, Paocharoen V. Efficacy of antimicrobial coating suture coated polyglactin 910 with triclosan (Vicryl Plus) compared with polyglactin 910 (Vicryl) in reduced surgical site infection of appendicitis, double blind randomized control trial, preliminary safety report. J Med Assoc Thail 2009; 92(6): 770-775.
16. Rozzelle CJ, Leonardo J, Li V. Antimicrobial suture wound closure for cerebrospinal fluid shunt surgery: a prospective, doubleblinded, randomized controlled trial. J Neurosurg Pediatr 2008; 2(2): 111-117.
17. Williams N, Sweetland H, Goyal S, Ivins N, Leaper DJ. Randomized trial of antimicrobial-coated sutures to prevent surgical site infection after breast cancer surgery. Surg Infect (Larchmt) 2011; 12(6): 469-474.
18. Chen SY, Chen TM, Dai NT, et al. Do antibacterial-coated sutures reduce wound infection in head and neck cancer reconstruction? Eur J Surg Oncol 2011; 37(4): 300-304.
19. Isik I, Selimen D, Senay S, Alhan C. Efficiency of antibacterial suture material in cardiac surgery: a double-blind randomized prospective study. Heart Surg Forum 2012; 15(1): E40-E45.
20. Stadler S, Fleck T. Triclosan-coated sutures for the reduction of sternal wound infections? a retrospective observational analysis. Interact Cardiovasc Thorac Surg 2011; 13(3): 296-299.
21. Thimour-BergströmL, Roman-Emanuel C, Scherstén H, Friberg Ö, Gudbjartsson T, Jeppsson A. Triclosan-coated sutures reduce surgical site infection after open vein harvesting in coronary artery bypass grafting patients: a randomized controlled trial. Eur J Cardiothorac Surg 2013; 44(5): 931-938.
22. Nakamura T, Kashimura N, Noji T, et al. Triclosan-coated sutures reduce the incidence of wound infections and the costs after colorectal surgery: a randomized controlled trial. Surgery 2013; 153(4): 576-583.
23. Alexander JW, Rahn R, Goodman HR. Prevention of surgical site infections by an infusion of topical antibiotics in morbidly obese patients. Surg Infect (Larchmt) 2009; 10(1): 53-57.
24. Millbourn D, Cengiz Y, Israelsson LA. Effect of stitch length on wound complications after closure of midline incisions: a randomized controlled trial. Arch Surg 2009; 144(11): 1056-1059.
25. Coello R, Charlett A, Wilson J, Ward V, Pearson A, Borriello P. Adverse impact of surgical site infections in English hospitals. J Hosp Infect 2005; 60(2): 93-103.
26. Astagneau P, Rioux C, Golliot F, Brucker G. Morbidity and mortality associated with surgical site infections: results from the 1997-1999 INCISO surveillance. J Hosp Infect 2001; 48(4): 267-274.
27. Fukuda H, Morikane K, Kuroki M, et al. Impact of surgical site infections after open and laparoscopic colon and rectal surgeries on postoperative resource consumption. Infection 2012; 40(6): 649-659.
28. Merle V, Germain JM, Chamouni P, et al. Assessment of prolonged hospital stay attributable to surgical site infections using appropriateness evaluation protocol. Am J Infect Control 2000; 28(2): 109-115.
29. Savarese DMF, Zand JM. UpToDate drug information. Wolters Kluwer Health, 2013.
30. Truven Health Analytics. Micromedex solutions. http://www. micromedexsolutions. com/micromedex2/librarian. Accessed 2013.
31. MMS. A regional distributor with a national presence. http://www. mmsmedical. com.
32. Whitehall Group. Medical and dental supplies. http://twgmedicalsupplies. com.
33. Agency for Healthcare Research and Quality, US Department of Health and Human Services. HCUPnet. National and regional estimates on hospital use for all patients from the Healthcare Cost and Utilization Project (HCUP) Nationwide Inpatient Sample (NIS) 2010 (see "National Statistics on All Stays"). http://hcupnet. ahrq. gov. Accessed March 2013.
34. American Medical Association. CPT code/relative value search. 2012. https://ocm. ama-assn. org/OCM/CPTRelativeValueSearch. do. Accessed February, 2013.
35. Physicians' Desk Reference staff. Red Book: Pharmacy's Fundamental Reference. Montvale, NJ: Thompson Reuters (Healthcare), 2010.
36. Gould MK, Dembitzer AD, Sanders GD, Garber AM. Lowmolecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A costeffectiveness analysis. Ann Intern Med 1999; 130(10): 789-799.
37. Human Mortality Database. University of California, Berkeley (USA), and Max Planck Institute for Demographic Research (Germany); 2008. http://www. mortality. org.
38. Bureau of Labor Statistics. Occupational employment statistics: May 2011 National Occupational Employment and Wage Estimates, United States. 2013. http://www. bls. gov/oes/current/oes_nat. htm#00-0000. Accessed February 2013.
39. Ceydeli A, Rucinski J, Wise L. Finding the best abdominal closure: an evidence-based review of the literature. Curr Surg 2005; 62(2): 220-225.
40. Israelsson LA, Jonsson T. Suture length to wound length ratio and healing of midline laparotomy incisions. Br J Surg 1993; 80(10): 1284-1286.
41. Shorr AF, Tabak YP, Killian AD, Gupta V, Liu LZ, Kollef MH. Healthcare-associated bloodstream infection: a distinct entity? insights from a large U. S. database. Crit Care Med 2006; 34(10): 2588-2595.
42. Graves N. Economics and preventing hospital-acquired infection. Emerg Infect Dis 2004; 10(4): 561-566.
43. Graves N, Halton K, Lairson D. Economics and preventing hos-pital-acquired infection: broadening the perspective. Infect Control Hosp Epidemiol 2007; 28(2): 178-184.
44. Belizon A, Balik E, Feingold DL, et al. Major abdominal surgery increases plasma levels of vascular endothelial growth factor: open more so than minimally invasive methods. Ann Surg 2006; 244(5): 792-798.
45. Friberg O, Dahlin LG, Levin LA, et al. Cost effectiveness of local collagen-gentamicin as prophylaxis for sternal wound infections in different risk groups. Scand Cardiovasc J 2006; 40(2): 117-125.
46. Horiuchi T, Tanishima H, Tamagawa K, et al. Randomized, controlled investigation of the anti-infective properties of the Alexis retractor/protector of incision sites. J Trauma 2007; 62(1): 212-215.
47. Yurko Y, McDeavitt K, Kumar RS, et al. Antibacterial mesh: a novel technique involving naturally occurring cellular proteins. Surg Innov 2012; 19(1): 20-26.
48. Alexander JW, Solomkin JS, Edwards MJ. Updated recommendations for control of surgical site infections. Ann Surg 2011; 253(6): 1082-1093.
49. Dubas ST, Wacharanad S, Potiyaraj P. Tunning of the antimicrobial activity of surgical sutures coated with silver nanoparticles. Colloids Surf A 2011; 380(1-3): 25-28.
50. Chang WK, Srinivasa S, Morton R, Hill AG. Triclosan-impregnated sutures to decrease surgical site infections: systematic review and meta-analysis of randomized trials. Ann Surg 2012; 255(5): 854-859.
51. Wang ZX, Jiang CP, Cao Y, Ding YT. Systematic review and meta-analysis of triclosan-coated sutures for the prevention of surgical-site infection. Br J Surg 2013; 100(4): 465-473.
52. Gervaz P, Bandiera-Clerc C, Buchs NC, et al. Scoring system to predict the risk of surgical-site infection after colorectal resection. Br J Surg 2012; 99(4): 589-595.
53. van Walraven C, Musselman R. The surgical site infection risk score (SSIRS): a model to predict the risk of surgical site infections. PLoS ONE 2013; 8(6): e67167.
54. Urban JA. Cost analysis of surgical site infections. Surg Infect (Larchmt) 2006; 7(Suppl 1): S19-S22.
55. Ford HR, Jones P, Gaines B, Reblock K, Simpkins DL. Intraoperative handling and wound healing: controlled clinical trial comparing coated VICRYL plus antibacterial suture (coated polyglactin 910 suture with triclosan) with coated VICRYL suture (coated polyglactin 910 suture). Surg Infect (Larchmt) 2005; 6(3): 313-321.
56. Yazdankhah SP, Scheie AA, Hoiby EA, et al. Triclosan and antimicrobial resistance in bacteria: an overview. Microb Drug Resist 2006; 12(2): 83-90.
57. Chuanchuen R, Beinlich K, Hoang TT, Becher A, Karkhoff-Schweizer RR, Schweizer HP. Cross-resistance between triclosan and antibiotics in Pseudomonas aeruginosa is mediated by multidrug efflux pumps: exposure of a susceptible mutant strain to triclosan selects nfxB mutants overexpressing MexCD-OprJ. Antimicrob Agents Chemother 2001; 45(2): 428-432.
58. Birošová L, Mikulášová M. Development of triclosan and antibiotic resistance in Salmonella enterica serovar Typhimurium. J Med Microbiol 2009; 58(4): 436-441.
59. Lee BY. Digital decision making: computer models and antibiotic prescribing in the twenty-first century. Clin Infect Dis. 2008; 46(8): 1139-1141.
60. Lee BY, Biggerstaff BJ. Screening the United States blood supply for West Nile virus: a question of blood, dollars, and sense. PLoS Med 2006; 3(2): e99. doi: 10. 1371/journal. pmed. 0030099.